IpamorelinGhrelin-receptor agonist · research
Ipamorelin stimulates a receptor involved in growth-hormone release and gut function. Its early pharmacology and postoperative research should not be mistaken for evidence of reliable fitness or anti-ageing benefits.
What is Ipamorelin?
Ipamorelin is a synthetic peptide growth-hormone secretagogue. It has also been investigated in gastrointestinal-motility research.
How it works
It activates the ghrelin receptor, influencing growth-hormone release and pathways related to appetite and gut activity.
Effects studied
Hormone responses in animals
The often-cited 1998 paper studied rat pituitary cells, rats and swine. It describes hormone responses in those models, not clinical benefits in people. 1
Evidence: Preclinical evidence
Recovery after bowel surgery
A later randomised trial tested intravenous ipamorelin after bowel surgery. Of 117 enrolled patients, 114 entered the analysis. Time to tolerating a solid meal did not differ significantly from placebo, and neither did the secondary efficacy outcomes. This was not evidence of faster postoperative recovery. 2
Evidence: Randomised human trial; no significant efficacy advantage
Why its selectivity attracted interest
The early research was interested in more than raising growth hormone. In pigs, ipamorelin stimulated GH without the ACTH and cortisol elevations seen with some other secretagogues; those responses were not significantly different from GHRH. This suggested a more selective endocrine profile worth investigating. It is an animal finding, not evidence that users will recover faster or avoid hormonal side effects. 1
Evidence: Preclinical endocrine findings in pigs; a research rationale rather than a demonstrated human benefit.
What does the evidence show?
Animal pharmacology and a randomised postoperative trial with no significant efficacy benefit
One receptor, several effects
Ipamorelin is a short synthetic peptide that activates the growth hormone secretagogue receptor, also called the ghrelin receptor. Ghrelin signalling reaches beyond growth hormone to appetite and gastrointestinal function. Calling a compound selective does not mean that every downstream effect is desirable or clinically well understood.
From animal experiments to a surgical trial
The often-cited 1998 paper studied rat pituitary cells, rats and swine. It describes hormone responses in those models, not clinical benefits in people. 1
A later randomised trial tested intravenous ipamorelin after bowel surgery. Of 117 enrolled patients, 114 entered the analysis. Time to tolerating a solid meal did not differ significantly from placebo, and neither did the secondary efficacy outcomes. This was not evidence of faster postoperative recovery. 2
What hormone and postoperative findings leave open
An observed rise in growth hormone demonstrates receptor activity. It does not quantify strength, everyday function or sleep benefit. Similarly, findings after major surgery cannot establish the safety of a different preparation and route used repeatedly in a wellness setting. Each change creates a new clinical question.
Why its selectivity attracted interest
The early research was interested in more than raising growth hormone. In pigs, ipamorelin stimulated GH without the ACTH and cortisol elevations seen with some other secretagogues; those responses were not significantly different from GHRH. This suggested a more selective endocrine profile worth investigating. It is an animal finding, not evidence that users will recover faster or avoid hormonal side effects. 1
The safety signal needs its context
The FDA notes serious adverse events, including deaths, in the intravenous postoperative literature. That does not by itself establish that ipamorelin caused those deaths. It also does not support describing the compound as proven safe. The agency also highlights immune-reaction and impurity concerns and inadequate safety information for other injectable routes. 3
Safety & status
The FDA describes serious adverse events, including deaths, in intravenous clinical literature; this does not by itself establish causation. It also identifies immune-reaction, impurity and route-specific safety uncertainties. 3
Country and product status
FDA compounding safety information checked. This is not an EU or Swiss authorisation assessment.
Frequently asked questions
Is a growth-hormone response proof of muscle benefit?
No. Hormonal activity does not establish improved muscle function or recovery.
Does intravenous research establish injection safety for other uses?
No. The patient group, preparation, route and treatment setting all affect the interpretation. 3
Sources
This entry was rewritten from our research archive. References below are reading leads unless a completed check is explicitly noted; a full independent evidence and regulatory review is still pending.
- Raun et al. (1998): Ipamorelin, the first selective growth hormone secretagogue Preclinical research · Abstract; rat cells, rats and swine, not a human study; checked 2026-10-29
- Beck et al. (2014): Randomised trial of ipamorelin for postoperative ileus Primary research · PubMed abstract; full paper and supplements not reviewed; checked 2026-10-29
- FDA: Compounding substances with potential significant safety risks US regulator · Relevant substance entry; US safety notice, not an EU authorisation assessment; checked 2026-10-29
Research provenance
This name was discovered in the Superpower peptide index, archived 26 October 2026. Its ratings and reviewer attribution have not been adopted as our own. The archive informed this original editorial draft; independent source review is still pending.